BioSpace News Archive

Pelvic Rehabilitation Medicine, a national leader in endometriosis care, believes that when it comes to endometriosis, conducted a study of patients who received the PRM Protocol™ before their endometriosis excision surgery.

CD Genomics, a renowned provider of genomics services, is pleased to announce the launch of its latest offering, Targeted Region Sequencing (TRS).

SOPHiA GENETICS SA is pleased to announce that its annual general meeting of shareholders was held at the Company’s headquarters, La Piece 12, 1180 Rolle/VD, Switzerland, earlier at 14:00 CEST.

RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation of multispecific ophthalmic therapies, announced the appointment of Ronil Patel as Chief Business Officer, effective immediately.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces the results of the Annul General Meeting.

Moberg Pharma announces that 17,776,856 warrants of series 2023:1 were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%.

Findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 receptor agonist were reported, demonstrating semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease.

Novo Nordisk today presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease (CKD), at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA).

Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, presented novel study results at the 84th Scientific Sessions of ADA held June 21 to 24 in Orlando, Florida.